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Abstract 
In this review, we analyse the impact of oncogenic Ras mutations in mediating cancer drug resistance, 
and progress made in the abrogation of this resistance, through pharmacological targeting. At a 
physiological level, Ras is implicated in many cellular proliferation and survival pathways. However, 
mutations within this small GTPase can be responsible for the initiation of cancer, therapeutic 
resistance and failure and ultimately disease relapse. Often termed ‘undruggable’, Ras is notoriously 
difficult to target directly, due to its structure and intrinsic activity. Thus, Ras-mediated drug resistance 
remains a considerable pharmacological problem. However, with advances in both analytical 
techniques and novel drug classes, the therapeutic landscape against Ras is changing. Allele-specific, 
direct Ras-targeting agents have reached clinical trials for the first time, indicating there may, at last, 
be hope of targeting such an elusive but significant protein for better more effective cancer therapy. 
 
Abbreviations: AML, acute myeloid leukaemia; CRCs, cancer stem cells; FLT3, fms-like tyrosine kinase 
3; FTI, farnesyltransferase inhibitor; HNSCC, head and neck squamous cell carcinoma; EGFR, epidermal 
growth factor receptor; GAP, GTPase activating protein; GEF, guanine nucleotide exchange factor; 
lncRNAs, long non-coding RNAs; MAPK, mitogen-activated protein kinase; mCRC, metastatic colorectal 
cancer; MEK, MAPK kinase; NF-B, nuclear factor B; NRF2, nuclear factor erythroid 2-related factor 
2; NSCLC, non-small cell lung cancer; PI3K, phosphatidylinositol-3-kinase; PPI, protein-protein 
interaction; RBD, Ras binding domain; ROS, reactive oxygen species. RTK, receptor tyrosine kinase; 
SOS, son-of-sevenless; TKI, tyrosine kinase inhibitor. 
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Introduction 
Resistance to conventional therapeutic agents is an increasingly concerning issue across all areas of 
disease, including cancer. Whilst the heterogenous nature of cancer means there are many 
mechanisms resulting in drug resistance, Ras mutations underpin resistance to a variety of therapies 
(Hobbs, Der & Rossman, 2016; Prior, Hood & Hartley, 2020; Prior, Lewis & Mattos, 2012). Oncogenic 
mutations in this small GTPase, which occur in approximately 19% of all cancers, cause constitutive 
activation of proliferative and survival pathways (Prior, Hood & Hartley, 2020). This can abrogate the 
effects of standard chemotherapy and newer, receptor-targeted therapies. Examples of such 
resistance is seen across a wide range of cancers, including metastatic colorectal cancer (mCRC), non-
small cell lung cancer (NSCLC), pancreatic cancer, acute myeloid leukaemia (AML) and basal cell 
carcinoma (Li, Xie, Wolff & Abbruzzese, 2004; McMahon et al., 2019; Misale et al., 2012; Tao et al., 
2014). Thus, there is a distinct clinical need to target Ras pharmacologically. Whilst this has been 
particularly challenging due to structural difficulties and very high levels of intrinsic activity, significant 
developments have been made within the last decade.  Allele-specific, direct Ras-targeting reaching 
clinical trials present a new era of potential Ras therapeutics and increases the likelihood of 
overcoming this resistance mechanism. 
What is Drug Resistance? 
There are two general classes of resistance: intrinsic and acquired. Intrinsic resistance occurs due to 
overt pre-existing factors, including variations in protein expression levels (such as increased 
expression of the P-gp (MDR1) transporter), epigenetic modifications (including by the long non-
coding RNA HAND2-AS1 and chromatin modifier Jarid1A) and somatic mutations (such as in Ras) 
(Burrell, McGranahan, Bartek & Swanton, 2013; Gruber et al., 2012; Marusyk, Almendro & Polyak, 
2012; Sharma et al., 2010). Changes conferring drug resistance often co-exist, resulting in a resistance 
heterogeneity similar to that seen in the original disease itself (Gerlinger et al., 2012; Ramirez et al., 
2016).   
Acquired resistance is thought to occur for a number of reasons, including through pre-existing (but 
initially undetectable) and de novo mutations (Bhaduri et al., 2020; Russo et al., 2019).This is often 
identified weeks to months after treatment has commenced (Santoni-Rugiu et al., 2019). In recent 
times, the concept of disease clonal heterogeneity has provided greater insight into the causes of 
acquired resistance, suggesting that chemoresistance and disease relapse occur as a result of minor 
sub-clonal populations. Given that these likely contribute to the heterogenous nature of cancer, it 
seems likely that these also contribute to disease re-emergence and relapse (Bonnet & Dick, 1997; 
Gerlinger et al., 2012; Pattabiraman & Weinberg, 2014; Roy & Cowden Dahl, 2018; Seth et al., 2019). 
Within these minor clonal populations, mutations conferring drug resistance may exist at the early 
stages of disease, but remain dormant and undetectable upon first presentation (Pietrantonio et al., 
2017; Russo et al., 2018). When the bulk of the cancer is eliminated as a result of initial chemotherapy 
targeted at overt mutations, cells from this minor subclone proliferate and become dominant in the 
tumour bulk (Jones et al., 2019; McMahon et al., 2019).  
A second, related, resistance mechanism involves a very rare subpopulation of cells, known as cancer 
stem cells (CSCs). CSCs were first described in AML, but have since been applied to many other cancers 
including (but not limited to) breast cancer, colorectal cancer, myeloma and pancreatic 
adenocarcinoma (Bonnet & Dick, 1997; Koury, Zhong & Hao, 2017; Lapidot et al., 1994). CSCs have 
unique properties compared to bulk tumour cells: they are undifferentiated and have strong self-
renewal and proliferative capabilities. They typically remain in a quiescent state, thus avoiding 
chemotherapy targeted at rapidly dividing cells (as in bulk tumour cells). However, they do have the 
proliferative capacity to maintain and expand the tumour burden, as bulk tumour cells are eliminated 
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(Jordan, Guzman & Noble, 2006). These ‘stemness characteristics’ render this subset of cells 
intrinsically resistant to chemotherapy, with distinct immunophenotypic and molecular signatures 
(Bonnet & Dick, 1997). This includes increased expression of efflux transporter P-gp, and the ability to 
repair damaged DNA, a common method of inducing cancer cell death (Dean, Fojo & Bates, 2005; 
Pattabiraman & Weinberg, 2014).  
Certain pathways upregulated in CSCs have been linked to the increased self-renewal capacity seen in 
this subset of cells. Key examples include the Wnt/-catenin and Hedgehog (Hh) pathways, as well as 
the Ras-dependent MAPK and PI3K/AKT pathways. Of these, the Wnt/-catenin pathway is perhaps 
the most associated with CSCs. Briefly, at a physiological level, Wnt signalling is not active, and -
catenin is ubiquitinated and sent for proteasomal degradation following interaction with GSK3, APC 
and Axin. In CSCs however, activation of Wnt signalling inhibits formation of the -catenin-GSK3-
APC-Axin complex, stabilising -catenin. This translocates to the nucleus whereby it stimulates 
transcription of proliferative genes, including c-Myc. This promotes proliferative signalling, increasing 
the self-renewal capacity of CSCs (Krausova & Korinek, 2014; Moon, Jeong, Park, Kim, Min do & Choi, 
2014). Although still ambiguous, it has been reported that -catenin stabilisation can promote Ras 
stabilisation and protects Ras against proteasomal degradation (Jeong, Ro & Choi, 2018; Lee et al., 
2018). This in turn promotes MAPK and PI3K pathway signalling, further contributing to the self-
renewal capacity of CSCs.  
Alternatively, upregulation of the Hh signalling pathway has been shown in CSCs. Whilst there are 
many facets to this pathway, its activation can stimulate upregulation of stemness-associated 
transcription factors including NANOG, OCT4 and SOX2, thus promoting self-renewal (Boyer et al., 
2005; Po et al., 2010; Takahashi & Yamanaka, 2006; Zhu et al., 2019). Increased activation and 
stabilisation of these genes (through either Hh signalling or biochemical stresses) have been 
implicated in the dedifferentiation of bulk tumour cells to CSCs (Herreros-Villanueva et al., 2013; 
Kumar et al., 2012). 
Interest in epigenetic remodelling has grown considerably in the last decade, and it has considerable 
effects in promoting drug resistance. Long non-coding RNAs (lncRNAs) are also implicated in survival 
of CSCs. In hepatocellular carcinoma, the lncRNA HAND2-AS1 is upregulated and stimulates the self-
renewal capacity of CSCs, through activation of the BMP signalling pathway. BMP activation has in 
turn been shown to induce chemoresistance in other cancer models, such as lung cancer (Gruber et 
al., 2012; Wang et al., 2015). Indeed, this pathway is also regulated by the fusion gene CBFA2T3-GLIS2 
and the Hh and JAK-STAT signalling pathways (Gruber et al., 2012; Okada et al., 2014).  
 
Taken together, it is evident that many signalling pathways and associated factors play a critical role 
in mediating drug resistance. Identifying commonalities between these pathways could present an 
opportunity to reduce the incidence and impact of drug resistance. Although the incidence of Ras 
mutations in CSCs is relatively low, Ras-mediated pathways have been implicated (Corces-
Zimmerman, Hong, Weissman, Medeiros & Majeti, 2014). In addition to the aforementioned -
catenin-mediated stabilisation of Ras, stabilised OCT4 and SOX2 expression has also been shown in 
response to AKT activation, by extracellular biochemical and radiation stresses (Maiuthed et al., 2018; 
Park et al., 2021). Indeed, activation of the MAPK pathway through the Ras-Raf interaction promotes 
increased expression of SOX2 and NANOG (Chan et al., 2018; Du et al., 2019). Furthermore, correlation 
has been seen between upregulation of the MAPK, PI3K and BMP pathways in drug-resistant lung 
cancer (Wang et al., 2015). Thus, not only can these pathways contribute to an increased cellular 
proliferation rate in bulk cancer, but they can also assist with the self-renewal and stemness properties 
evident in CSCs. Perhaps unsurprisingly, inhibition of the Hh signalling pathway, when combined with 
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inhibition of mTOR (downstream of AKT) has been seen to eliminate CSCs in pancreatic cancer 
(Mueller et al., 2009; Prieur et al., 2017). Furthermore, MEK inhibition has been implicated in reduced 
pancreatic CSC survival (Walter et al., 2019). 
Key examples of drug-resistance in cancer 
In recent years, resistance has been documented amongst many cancer therapeutics, including 
traditional chemotherapeutic agents, and more novel small molecule inhibitors and monoclonal 
antibodies (Caiola et al., 2015; McMahon et al., 2019; Pietrantonio et al., 2017). The origin of this 
resistance (intrinsic or acquired) varies considerably between drugs, and so advances have been made 
in treatment stratification, based on a patient’s mutational status, for some therapies. For example, 
vemurafenib, the BRAF-inhibitor, is restricted to melanoma patients with the BRAF V600E mutation 
(Hopkins, Van Dyk, Rowland & Sorich, 2019). Likewise, the monoclonal antibody panitumumab is only 
recommended for patients with wild-type Ras (Amado et al., 2008). However, as mentioned 
previously, some mutations are only detectable when patients relapse, such as the emergence of FLT3 
or NRAS mutations in AML patients (Man et al., 2012; McMahon et al., 2019; Piloto, Wright, Brown, 
Kim, Levis & Small, 2007; Smith et al., 2017). Many of these mutations occur downstream of the site 
targeted by the drug. For example, since Ras operates downstream of the epidermal growth factor 
receptor (EGFR), Ras mutations play a role in rendering cetuximab and panitumumab (which bind and 
inhibit EGFR) ineffective as the constitutive activation is not inhibited by the drug (De Roock et al., 
2010; Li, Liu, Chi, Sun, Cheng & Cheng, 2015; Zhao et al., 2017). However, some of these putative 
resistance-causing mutations can only be detected at relapse, once they have expanded from only 
existing in a minor, undetectable subclone (as they did at diagnosis). Thus, it is difficult to predict 
which patients will develop these resistance mutations, meaning initial treatment stratification is 
difficult. Thus, combination therapy between these established agents and novel agents targeting 
these common mutational sites may be a way forward in preventing resistance before it occurs, an 
example of which is the combination of BRAF and MEK inhibitors, vemurafenib and cobimetinib 
(Hopkins, Van Dyk, Rowland & Sorich, 2019). 
Introduction to Ras 
As eluded, Ras mutations underpin resistance to a variety of therapies. KRAS is most commonly 
mutated of the three Ras isoforms, and is particularly frequently mutated in lung and pancreatic 
cancer (Moore, Rosenberg, McCormick & Malek, 2020; Prior, Hood & Hartley, 2020). However, 
patterns of Ras mutation differ between cancers and NRAS is the most frequently mutated Ras gene 
in AML, and HRAS accounts for most Ras mutations in head and neck squamous cell carcinoma 
(HNSCC) (Prior, Hood & Hartley, 2020) . Indeed, this variation carries varying prognoses of Ras-mutated 
cancer, with KRAS mutations conferring lowest overall survival 5 years post diagnosis (43%), and HRAS 
mutations conferring the highest (63%) (Figure 1) (Cerami et al., 2012; Gao et al., 2013).  
Most oncogenic mutations in Ras occur in the residues G12, G13 and Q61, which are located in a region 
conserved between HRAS, KRAS and NRAS (figure 2A). They occur within the effector lobe, which 
comprises the first 85 amino acids and is a region of complete sequence identity between the different 
RAS isoforms. Most key interaction sites occur within the effector lobe, including nucleotide and 
effector interaction sites, as well as the switch regions that mediate effector interactions (figure 2B). 
There is 90% similarity in the next 80 amino acids (allosteric lobe). The only considerable sequence 
differences occur at the C terminal end of the protein, known as the hypervariable region. This is the 
region in which post-translational modifications occur, and membrane-targeting sequences are found 
(Hobbs, Der & Rossman, 2016). Initial attempts at direct pharmacological targeting of Ras centred 
around inhibiting these post-translational modifications, including farnesylation (Cox & Der, 2002; 
Whyte et al., 1997), however more recent attempts have considered the effector lobe, and structures 
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within this, to be better therapeutic targets, as discussed later (Canon et al., 2019; Janes et al., 2018; 
Ostrem, Peters, Sos, Wells & Shokat, 2013).  
Ras is activated or inactivated when bound to GTP or GDP, respectively. Oncogenic mutations increase 
the frequency of GTP-bound (active) Ras, through two key mechanisms. This is through either 
decreasing the affinity of Ras for GTPase Activating Proteins (GAPs), which stimulate the intrinsic 
GTPase activity of Ras and therefore facilitate hydrolysis of GTP to GDP (off/inactivating mechanism), 
or by decreasing the need for Guanine nucleotide Exchange Factors (GEFs), which mediate the 
on/activating mechanism (Smith, Neel & Ikura, 2013; Wittinghofer & Waldmann, 2000). These 
differences depend on multiple factors including the specific amino acid mutation and resulting 
protein conformation (Hunter, Manandhar, Carrasco, Gurbani, Gondi & Westover, 2015; Miller & 
Miller, 2012; Poulin et al., 2019; Prior, Lewis & Mattos, 2012; Smith, Neel & Ikura, 2013), some 
mutations (including G12C) promote rapid cycling between the inactive and active states, an area 
which has been exploited by a range of novel Ras-targeting drugs (Fell et al., 2020; Hunter, 
Manandhar, Carrasco, Gurbani, Gondi & Westover, 2015; Patricelli et al., 2016).  
Ras Signalling – Regular and Oncogenic 
Ras is involved in key pathways regulating cell proliferation, differentiation and sensitivity to 
apoptosis, perhaps the most notable being the MAPK pathway and the PI3K/AKT pathway. KRAS has 
also been implicated (albeit in a more indirect way) in a  range of other pathways, including the Wnt/-
catenin pathway and the NRF2 pathway (DeNicola et al., 2011; Ferino, Rapozzi & Xodo, 2020; Moon, 
Jeong, Park, Kim, Min do & Choi, 2014; Park et al., 2019; Tao et al., 2014). These pathways are detailed 
briefly below and are summarised in figure 3.  
Ligand-binding to receptor tyrosine kinases (RTKs) such as EGFR or FLT3, causes autophosphorylation 
of key tyrosine residues on the RTK, after which adaptor proteins such as Grb2 bind to these 
phosphorylated tyrosines via SH2 domains. SOS, a Ras-GEF, then associates with Grb2 via two SH3 
domains, and ultimately facilitates the exchange of GDP for GTP on RAS, thereby activating it 
(Freeman, 2000).  
Following this, Ras stimulates recruitment of its serine-threonine kinase effector, RAF, to the 
membrane, which binds through its Ras binding domain (RBD) then proceeds to phosphorylate 
downstream kinases including MEK and ERK (Marais, Light, Paterson & Marshall, 1995; Molina & Adjei, 
2006). ERK then translocates from the cytoplasm to the nucleus, causing the activation of many 
transcription factors, which go on to regulate a host of processes, including proliferation and 
differentiation (Guo, Pan, Liu, Shen, Xu & Hu, 2020; Zhang & Liu, 2002).  
Alternatively, activated Ras can promote the PI3K-AKT pathway. This pathway also plays a key role in 
controlling survival, division and metabolism, and can be activated in many different ways (Castellano 
& Downward, 2011; Mendoza, Er & Blenis, 2011). Ras binds and activates the p110 catalytic subunit 
of PI3K, which in turn promotes transformation of the plasma membrane-bound lipid PIP2 to PIP3, and 
activation of AKT by binding through PH domains (Cantley, 2002; Castellano & Downward, 2011). AKT 
interacts with many downstream effectors, including MDM2, BAX, BAD and NF-kB. These interactions 
regulate apoptosis (Cantley, 2002; Castellano & Downward, 2011; Chang et al., 2003; Duronio, 2008). 
Furthermore, activation of FOXO by AKT promotes cellular metabolism (Engelman, Luo & Cantley, 
2006). Given that the MAPK and PI3K pathways are both strongly involved in controlling cell survival 
and death, it is clear that aberrant signalling within these pathways will lead to cancer, of which key 
hallmarks include sustaining proliferative signalling, enabling replicative immortality and resisting cell 
death (Hanahan & Weinberg, 2011).  
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Aside from these two classic Ras-dependent pathways, increasing evidence suggests the implication 
of normal and mutant Ras function in alternative mechanisms, such as redox homeostasis and stem 
cell survival (Mukhopadhyay et al., 2020; Wu, Lu & Bai, 2019). The role of Ras in CSCs is yet to be fully 
elucidated, however its crosstalk with the Wnt/-catenin pathway in tumorigenesis may suggest its 
involvement in the maintenance of CSCs (Moon, Jeong, Park, Kim, Min do & Choi, 2014).  It is 
understood that, in colorectal cancer, there is overactivation of both the Wnt/-catenin and Ras 
pathways, through mutations within APC (a tumour suppressor) and KRAS, respectively (Jeong, Ro & 
Choi, 2018). There is a synergistic effect seen with these mutations (D'Abaco, Whitehead & Burgess, 
1996; Janssen et al., 2006; Jeong, Ro & Choi, 2018; Margetis, Kouloukoussa, Pavlou, Vrakas & Mariolis-
Sapsakos, 2017). Mutations within APC cause loss of function of the tumour suppressor gene, whilst 
KRAS mutations lead to phosphorylation of key tyrosine residues within -catenin, causing its 
accumulation within the cytoplasm. This ultimately increases activation of downstream Wnt pathway 
target genes, including REG4, a marker of CSCs (Hwang, Yoon, Cho, Cha, Park & Choi, 2020; Janssen et 
al., 2006). Upregulation of this pathway is highly associated with the increased survival and plasticity 
properties seen in CSCs and has been seen in many cancers (Al-Hajj, Wicha, Benito-Hernandez, 
Morrison & Clarke, 2003; Koury, Zhong & Hao, 2017; Lapidot et al., 1994). Taken together, it seems 
plausible that these KRAS mutations may play a role in the protection of the minor subset of cells 
which likely have a key role in relapse.  
Furthermore, Ras mutations can also be implicated in reactive oxygen species (ROS) 
generation/detoxification. ROS are considered a ‘double-edged sword’, capable of both helping and 
hindering cancer cells (Hayes & McMahon, 2006; Wu, Lu & Bai, 2019). At physiological levels of ROS, 
NRF2 binds Keap1 and is ubiquitinated and degraded on a regular basis. However, upon detection of 
high levels of ROS (which is carcinogenic), NRF2 is unable to bind to Keap1 (due to conformational 
changes in Keap1) and so translocates to the nucleus, where it acts as a transcription factor for various 
downstream detoxification genes. Hence, the DNA of the healthy cells remains undamaged by ROS 
(Basak, Sadhukhan, Sarkar & Sil, 2017; Gorrini, Harris & Mak, 2013). However, in cancer, the NRF2 
pathway can be upregulated to constitutively degrade ROS (induced by chemotherapeutics), thereby 
conferring a protective effect to the cancer cells, resulting in chemoresistance (Basak, Sadhukhan, 
Sarkar & Sil, 2017; Gorrini, Harris & Mak, 2013). Therefore, the balance of NRF2 activation level is 
crucial. In the last decade, it has been shown that KRAS G12D mutations can increase NRF2 
transcription, through activation of the TPE Response Element via the MAPK pathway (DeNicola et al., 
2011; Mukhopadhyay et al., 2020; Shirazi et al., 2020; Tao et al., 2014). Thus, these KRAS mutations 
can render the cancer cell more capable of coping with chemotherapy-induced ROS, thereby 
mediating drug resistance. 
The Involvement of Ras in Chemotherapy Resistance  
Should mutations occur as described above, it follows that one or many of these pathways can be 
perturbed, leading to increased cell proliferation, decreased cell death and promotion of CSCs, 
amongst other effects. The following scenarios illustrate some of these key resistance mechanisms, 
highlighting the necessity for better Ras-targeting. 
Platinum-based agents, such as cisplatin, carboplatin and oxaliplatin, are used in the treatment of a 
variety of cancers, including HNSCC, testicular cancer and non-small cell lung cancer (NSCLC) (de Vries, 
Rosas-Plaza, van Vugt, Gietema & de Jong, 2020; Silva, Rocha, Kinker, Pelegrini & Menck, 2019; 
Weykamp et al., 2020). They are DNA intercalating agents that interfere with RNA transcription and 
DNA replication, through cross-linking of DNA. This results in the formation of DNA adducts, which in 
turn drive the tumour cell to apoptosis. Cisplatin also induces mitochondrial ROS, which further 
increase DNA damage and thus increase the cytotoxic properties of the drug (Marullo et al., 2013; 
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Srinivas, Tan, Vellayappan & Jeyasekharan, 2019). However, there are many resistance mechanisms 
associated with cisplatin, including the involvement of oncogenic KRAS mutations (Caiola et al., 2015; 
DeNicola et al., 2011; Feldman et al., 2014; Garassino et al., 2011). KRAS mutations were shown to 
induce NRF2 pathway upregulation in NSCLC, thereby decreasing cisplatin-induced ROS within the 
tumour cell, and ultimately leading to decreased cell death (DeNicola et al., 2011). This was supported 
by further work indicating oncogenic KRAS can induce NRF2 gene transcription via the TPE response 
element, resulting in the overactivation of the anti-oxidative stress pathway, rendering the tumour 
cells resistant to cisplatin-induced ROS (Tao et al., 2014). Furthermore, KRAS mutations can lead to 
hyperactivation of the PI3K-AKT pathway, which is starting to be implicated as a cisplatin resistance 
mechanism. As mentioned, upregulation of the PI3K-AKT-mTOR pathway can have multiple effects, 
including inhibition of apoptosis and increased cell proliferation (de Vries, Rosas-Plaza, van Vugt, 
Gietema & de Jong, 2020). Whilst there are other reasons for cisplatin resistance, Ras pathway 
mutations are heavily implicated in the key mechanisms. Thus, pharmacologically targeting Ras would 
provide an opportunity to overcome many causes of this resistance. 
Upregulation of Ras-mediated pathways as a means of chemoresistance is by no means restricted to 
cisplatin resistance, and is a common mechanism of resistance to tyrosine kinase inhibitors (TKIs), such 
as those targeting RTKs including FLT3 and EGFR (Eberlein et al., 2015; Massarelli et al., 2007; 
McMahon et al., 2019; Ortiz-Cuaran et al., 2016; Piloto, Wright, Brown, Kim, Levis & Small, 2007; Van 
Emburgh et al., 2016). TKIs are used in a variety of cancers, including renal cell carcinoma (RCC), 
colorectal cancer (CRC), AML and NSCLC, to name a few examples. The mechanism of action of TKIs 
involves inhibition of phosphorylation sites within the protein, thereby preventing it exerting kinase 
activity on downstream effectors (Ciardiello & Tortora, 2008; Yamaoka, Kusumoto, Ando, Ohba & 
Ohmori, 2018). However, resistance to these can occur through two predominant mechanisms: 
mutations within the RTK, or mutations within downstream pathways (McMahon et al., 2019; Piloto, 
Wright, Brown, Kim, Levis & Small, 2007; Van Emburgh et al., 2016; Yu et al., 2013). Given that Ras 
occurs downstream of these receptors, any mutations within Ras will render the cell resistant to the 
TKI. For example, studies have shown KRAS mutations render patients resistant to gefitinib, used to 
treat NSCLC (Pao et al., 2005; Zhao et al., 2017). In a similar way, the treatment of CRC with anti-EGFR 
monoclonal antibodies cetuximab or panitumumab is only successful in a subset of patients, with 
many eventually developing resistance (Pietrantonio et al., 2017). This has been attributed to Ras 
mutations and variations in the EGFR extracellular domain (ECD), which reduce antibody binding 
efficiency, ultimately initiating relapse (Van Emburgh et al., 2016). Although cetuximab and 
panitumumab are only prescribed to Ras wild-type patients, emergence of mutations from 
undetectable, pre-existing clones can give rise to resistance in this way, as evidenced through analysis 
of circulating tumour DNA (ctDNA) (Amirouchene-Angelozzi, Swanton & Bardelli, 2017; Diaz et al., 
2012; Misale et al., 2012). The order in which these mutations develop/emerge is likely important in 
understanding (and ultimately targeting) the process of relapse: Ras mutations often develop earlier 
than EGFR ECD variations, and typically confer poorer prognosis (Van Emburgh et al., 2016). Therefore, 
combatting these Ras mutations would not only improve prognosis of Ras-mutated patients, but also 
provide a second therapeutic option for those that go on to develop ECD variations. 
Resistance to FLT3-TKIs is also a highly prevalent issue. It is well-documented that 20-30% of AML 
patients have an internal tandem duplication in the FLT3 receptor tyrosine kinase (FLT3-ITD) causing 
increased cell proliferation and decreased apoptosis, via the MAPK, STAT5 and PI3K pathways 
(Hayakawa et al., 2000; Moore et al., 2020; Papaemmanuil et al., 2016; The Cancer Genome Atlas, 
2013). Therefore, many different FLT3 inhibitors are at varying stages in development to overcome 
the effects of this mutation.  Examples include gilteritinib, crenolanib and midostaurin (Aikawa et al., 
2020; McMahon et al., 2019; Piloto, Wright, Brown, Kim, Levis & Small, 2007; Zhang et al., 2019). 
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These TKIs bind to the active conformation of FLT3 and are at varying stages of approval: gilteritinib 
and midostaurin are FDA-approved, crenolanib is in phase II trials (Galanis et al., 2014; Levis, 2017; 
Levis et al., 2011; Zhang et al., 2019). Whilst results for these drugs have all been promising, subsets 
of patients exhibit resistance. This has, in part, been attributed to Ras mutations, re-activating the 
MAPK and PI3K-AKT pathways (McMahon et al., 2019; Zhang et al., 2019). These mutations were 
detected in over 30% of patients who developed resistance to gilteritinib, with Ras variant allele 
frequencies also increasing post-drug exposure in patients who responded poorly to crenolanib. 
Interestingly, not all resistant patients had FLT3 mutations following treatment either, with different 
mutational signatures present instead (McMahon et al., 2019; Zhang et al., 2019). This implies a clonal 
selection mechanism of resistance – a minor subpopulation at diagnosis which became dominant 
following treatment and elimination of the initial tumour burden. Taken together, it seems likely these 
Ras mutations, either pre-existing or de novo, may contribute to resistance to FLT3 inhibitors, through 
restoration of the original disease phenotype by expansion of an originally minor subclone. This is 
perhaps unsurprising in AML, which arises as a result of clonal haematopoiesis (Desai et al., 2018).  
Options for Targeting the Ras pathway 
With improved capability of detecting minor cancer subclones, alongside the greater understanding 
of the impact of Ras mutations in various cancers, the next considerable challenge is improved 
pharmacological targeting of Ras. However, drugging Ras has proven exceptionally difficult. A key 
drawback is the lack of available binding sites for small molecule inhibitors. The nucleotide binding 
site (where GTP or GDP binds) seems a desirable pocket to target, however the picomolar affinity with 
which both GDP and GTP bind, as well as their high intracellular concentrations, effectively 
outcompete the binding of any drug at this site (Cox, Fesik, Kimmelman, Luo & Der, 2014; McCormick, 
2018). 
Therefore, targeting alternative proteins within Ras-regulated pathways has been strongly 
investigated, with positive results seen. For example, trametinib, the MEK inhibitor. Currently 
approved for patients with BRAF V600-mutant metastatic melanoma or BRAF-mutated (V600) NSCLC, 
trametinib is well-tolerated in patients (Lugowska, Koseła-Paterczyk, Kozak & Rutkowski, 2015; 
Odogwu et al., 2018), and is also being assessed in Ras-mutant myeloid malignancies (Borthakur et al., 
2016). This compound binds to phosphorylated MEK and inhibits its downstream effectors (e.g. ERK), 
despite the presence of constitutive Ras signalling. Subsequently, aberrant growth signalling and 
apoptosis inhibition is reduced (Hofmann et al., 2012). Whilst this has shown promising results 
(Borthakur et al., 2016; Lugowska, Koseła-Paterczyk, Kozak & Rutkowski, 2015; Odogwu et al., 2018), 
this compound only inhibits the MAPK pathway downstream of MEK, so constitutive activation of 
other Ras-dependent pathways (e.g. PI3K-AKT) will still occur in the presence of Ras mutations even 
when treated with this drug. In this way, cancer can persist (Jones et al., 2019; Stinchcombe & Johnson, 
2014). However, if Ras were to be targeted directly, signalling of both of these pathways would be 
inhibited, leading to cell death.  
As often seen with many diseases, combination of trametinib with other therapeutics to inhibit 
multiple pathways together may reduce the likelihood of continued cancer signalling and potential 
development of resistance to this and other drugs (Infante & Swanton, 2014; Planchard et al., 2016; 
Zhou, Zhao, Chen, Zhang & Zhou, 2020). However, even with the approved combination regimen of 
dabrafenib (BRAF inhibitor) with trametinib (Lugowska, Koseła-Paterczyk, Kozak & Rutkowski, 2015), 
only the MAPK pathway is inhibited, thereby maintaining the potential for aberrant PI3K pathway 
signalling, which can in itself cause resistance to MEK inhibitors (Jaiswal et al., 2009; Sos et al., 2009; 
Vitiello et al., 2019). 
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Alternatively, positive effects have been shown in vitro and in vivo of co-administering AKT inhibitors 
with dabrafenib to inhibit two Ras-mediated pathways (Lassen et al., 2014). However, combination of 
the two classes of drugs in patients did not yield significant clinical activity in reducing resistance seen 
in trametinib monotherapy, with 25% of patients exhibiting grade 3-4 toxicity (Algazi et al., 2018).  
Taken together, whilst downstream pathway inhibition has proved successful, this treatment method 
does have considerable disadvantages and may not be a long-term solution for many patients. 
Therefore, there is a distinct clinical need for novel means of treating Ras-mutant cancers, which could 
include the targeting of Ras itself. 
Given the difficulties with targeting Ras, inhibition of elements upstream of Ras has been investigated. 
This includes inhibition of GEFs including SOS1, to reduce the likelihood of Ras maintaining its GTP-
bound state and therefore inhibiting constitutive signalling (Evelyn, Duan, Biesiada, Seibel, Meller & 
Zheng, 2014; Hillig et al., 2019). For example, BAY293 is a first-in-class compound with the ability to 
bind directly to SOS1 and inhibit the Ras-SOS interaction, and thereby downstream signalling of the 
PI3K and MAPK pathways (Hillig et al., 2019). Although the in vivo bioavailability for this compound 
was poor, the concept of Ras-SOS inhibition could prove useful in the future, with promising high 
throughput in silico and in vitro screening results serving as a proof of concept for inhibition of Ras via 
this mechanism (Evelyn et al., 2015; Evelyn, Duan, Biesiada, Seibel, Meller & Zheng, 2014; Hillig et al., 
2019). More recently, BI-1701963, a SOS1-pan-Ras interaction inhibitor has reached Phase I clinical 
trials, the first of its kind to do so. Modified from the structure of BI-3406, a quinazoline-derived 
compound, this novel inhibitor binds to the catalytic site of SOS1, preventing its interaction with 
inactive KRAS, thus inhibiting activation (Gerlach et al., 2020; Hofmann et al., 2020).  
In addition, alternative, more indirect pathways are also being targeted as a means of inhibiting Ras, 
which may also be able to eliminate the CSC. For example, the small molecule KYA1797K has been 
shown to be effective against oncogenic Ras in CRC and erlotinib-resistant NSCLC (Park et al., 2019). 
This compound indirectly targets Ras, through inhibition of the Wnt/-catenin pathway, which usually 
stabilises Ras (Jeong et al., 2012; Moon, Jeong, Park, Kim, Min do & Choi, 2014). This pathway is also 
upregulated in CSCs (Malanchi et al., 2008). KYA1797K has initiated anti-tumour effects in KRAS-
mutant cell lines and a KRAS-mutated mouse model. KYA1797K also exhibited synergy with the current 
first line therapeutic regimen (cisplatin and pemetrexed) in NSCLC in vitro models (Park et al., 2019). 
However, KYA1797K promoted apoptosis of both KRAS wild type and mutant cells, questioning the 
specificity of the drug for cancer cells whilst sparing healthy cells. This study found both KRAS and -
catenin were overexpressed in tumour regions compared to non-tumour regions  (Park et al., 2019). 
This may explain the limited toxicity seen during KYA1797K studies, with low doses of KYA1797K 
having a more substantial effect on tumour cells, compared to healthy cells. Indeed, only limited 
toxicity was seen during in vivo studies (Park et al., 2019). However, protein expression varies 
considerably between tissues (with KRAS particularly highly expressed in the brain), and so targeting 
based on comparative expression between cancer and non-cancer regions in one tissue may not 
represent overall toxicity potential (Newlaczyl, Coulson & Prior, 2017).  Taken together, there may be 
a role for KYA1797K as a concomitant therapy in NSCLC (as well as other cancers such as CRC). It 
presents a means of eliminating both the primary cause of the disease (if KRAS-mutated), and also 
minor subclones and CSCs that could give rise to resistance (Cho et al., 2020). Nevertheless, better 
understanding of the drug’s effects on other tissues with high Ras expression must be gained.  
Options for Targeting Ras – Direct Ras Targeting 
Ras post-translational modifications were targeted as a means of preventing Ras trafficking to the 
membrane and therefore inhibiting downstream signalling. This included generation of 
farnesyltransferase inhibitors (FTIs), including lonafarnib and tipifarnib (Van Cutsem et al., 2004). 
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However, the effectiveness of these was questionable, with most patients with KRAS-mutated 
diseases (such as pancreatic cancer and leukaemia patients) receiving no clinical benefit from these 
FTIs (Borthakur et al., 2006; Burnett et al., 2012; Harousseau et al., 2009; Van Cutsem et al., 2004). 
Inefficacy was largely due to the redundancy mechanism of geranylgeranyltransferase, which 
sufficiently modifies KRAS in the absence of farnesyltransferase to permit its trafficking to the 
membrane (Basso, Kirschmeier & Bishop, 2006; Whyte et al., 1997). Interest in this strategy has 
recently been revived with new personalised medicine approaches now capable of identifying patients 
harbouring HRAS- or NRAS-driven cancers that are more likely to respond (Gilardi et al., 2020; Lee et 
al., 2020).  
In recent years however, more promising steps have been made regarding direct inhibition of 
oncogenic Ras. A key feature of this has been the discovery of novel potential binding pockets for small 
molecule inhibitors, to inhibit GEF activity or effector binding  (Cruz-Migoni et al., 2019; Maurer et al., 
2012; Ostrem, Peters, Sos, Wells & Shokat, 2013). Fragment-based screening identified a previously-
undiscovered hydrophobic pocket located between the Switch I and II regions (termed S-IIP), which 
was successfully targeted by Ostrem et al. (2013) (figure 4a). Binding of peptide fragments was specific 
to G12C-mutated KRAS since the compounds functioned through irreversible cysteine binding in this 
particular pocket (and not with other cysteines found in wild type KRAS). Other key residues within 
this pocket include, but are not limited to, V7, V9, M72, F78, Q99 and I100. In vitro models of KRAS 
G12C-mutated lung cancer treated showed decreased survival upon treatment with these 
compounds, with inactive Ras (RAS-GDP) levels considerably greater than Ras-GTP. Further analysis 
showed that the conformational disruption caused by binding of these fragments, reduced 
interactions with both SOS and effector molecules and pathways, including B-RAF, C-RAF and the PI3K 
pathway (Gentile et al., 2017; Ostrem, Peters, Sos, Wells & Shokat, 2013).  
The binding of these fragments to Ras also reduce SOS-catalysed nucleotide exchange, a method of 
Ras inhibition which had been previously explored. Compounds acting in this way either inhibited 
conversion of Ras-GDP to Ras-GTP (Patgiri, Yadav, Arora & Bar-Sagi, 2011), or increased the amount 
of Ras-GTP to such a level that it inhibited ERK phosphorylation, since overactivation of Ras can be 
cytotoxic (the Ras ‘sweet-spot model’)  (Li, Balmain & Counter, 2018). Either way, these compounds 
were shown to inhibit the MAPK pathway, but were largely tested against Ras wild type (in the context 
of inhibiting the effects of RTK mutations). Thus, the aforementioned compounds identified by Ostrem 
et al. were revolutionary in their specificity for targeting Ras-mutated disease.  
Discovery and characterisation of this SII-P pocket has led to the development of revolutionary KRAS 
G12C-selective covalent inhibitors, including ARS-853 and latterly AMG-510 (Figure 4B-D) (Canon et 
al., 2019; Patricelli et al., 2016). ARS-853 binds irreversibly to the inactive form of KRAS G12C, 
preventing exchange of GDP for GTP and therefore activation. This in turn inhibits downstream MAPK 
and PI3K—AKT pathway signalling, with KRAS-CRAF interactions significantly reduced. Moreover, in 
vitro evidence showed increased apoptosis and cell cycle arrest in some (but not all) models tested 
(Lito, Solomon, Li, Hansen & Rosen, 2016; Patricelli et al., 2016). This compound has subsequently 
been fully characterised in silico, and these studies revealed a dynamic nature of the SII-P pocket, a 
feature which could be utilised in further study (Khrenova, Kulakova & Nemukhin, 2020).  
Based on this work, alternative iterations of KRAS G12C inhibitors have been produced. This was 
required since the probability of ARS-853 locking KRAS in its inactive state in vivo was debatable, given 
a lack of understanding regarding the cycling efficiency of Ras between its inactive and active states. 
It had been deduced in vitro that the G12C mutation permits rapid cycling of KRAS between these 
states, hence permitting the binding of ARS-853 (figure 4B). However, the possibility of finding the 
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correct therapeutic window to translate this compound to in vivo work proved complex (Janes et al., 
2018; Lito, Solomon, Li, Hansen & Rosen, 2016; Patricelli et al., 2016). Thus, alternatives including ARS-
1620 were developed to improve in vivo capability (figure 4C). Modifications to the ARS-853 structure 
resulted in favourable pharmacokinetic (PK) properties, permitting a greater understanding of KRAS 
activation status and dependency in vivo (Janes et al., 2018). ARS-1620, is an orally bioavailable 
quinazoline based compound with limited side effects witnessed in pre-clinical animal models (Janes 
et al., 2018; Li, Balmain & Counter, 2018). Optimisation from ARS-853 by inclusion of a fluorophenol, 
hydrophobic binding group permitted stronger covalent (irreversible) binding within the SII-P pocket 
(more specifically, interaction with H95 in this pocket), thus improving potency (figure 4). The effects 
of this compound remained mutation-specific, thereby eliminating the risk of binding to KRAS wild-
type in non-tumour cells and thus reduced toxicity potential. This compound was well tolerated in 
patient-derived xenograft mice, where a reduction in tumour burden through decreased Ras-
mediated downstream signalling was evident. This was the first example of an in vivo trial using a 
compound targeting the SII-P pocket (Janes et al., 2018). 
From this, AMG-510 was developed, following further modifications to the ARS-1620 structure, 
including addition of more aromatic entities (figure 4D). This enables AMG-510 to bind within a slightly 
different groove of SII-P, enhancing potency and selectivity (Canon et al., 2019). Promising pre-clinical 
in vitro and in vivo experiments indicated arrest of the MAPK pathway and induction of a pro-
inflammatory tumour microenvironment. This compound has since progressed into clinical trials, the 
first KRAS-G12C selective inhibitor to do so. Early data indicates that, out of 29 patients evaluable for 
response at the time of publication, 5 exhibited partial response, 18 had stable disease and 6 had 
progressive disease. As with the previous ARS-1620 animal studies, AMG-510 was generally well-
tolerated, with no dose limiting toxicities recorded (Govindan, 2019; Romero, 2020). However, larger 
cohorts and longer trials are imperative in determining the true impact of this compound. Such 
compounds could help combat the KRAS-mediated resistance to monoclonal antibodies seen in NSCLC 
and CRC (Lièvre & Laurent-Puig, 2009; Park et al., 2019). However, success of this compound, and 
indeed this targeting mechanism, is likely restricted to KRAS-G12C mutant cancer since some key 
residues for binding of this compound are unique to KRAS and not conserved between the different 
isoforms. Indeed, in vitro work completed by Ostrem, Peters, Sos, Wells and Shokat (2013)  illustrated 
that transduction of lung cancer cell lines with KRAS G12V rescued the cancerous phenotype 
(resistance to cell death, increased proliferation), thereby illustrating how this mutation renders 
resistance to KRAS G12C inhibitors, as expected.  
Alternative KRAS G12C inhibitors are also in development and showing considerable promise, 
including MRTX849 (Fell et al., 2020; Hallin et al., 2020a). In a similar way to AMG-510 and the ARS 
compounds discussed above, MRTX849 covalently binds to the inactive form of KRAS, in SII-P (figure 
4E). This induces apoptosis through downregulation of the MAPK pathway. Interestingly, the PI3K-AKT 
pathway remained relatively unaffected by MRTX849 (Hallin et al., 2020b). In vivo trials with MRTX849 
exhibited favourable pharmacokinetic/pharmacodynamic properties (Fell et al., 2020), and both cell 
line- and  patient-derived xenograft modelling of pancreatic and lung cancers also indicated up to a 
30% reduction in tumour burden (Fell et al., 2020; Hallin et al., 2020b). Individual patient case studies 
from Phase I trials have also shown MRTX849 to be effective in reducing tumour burden in both lung 
and colorectal cancers, although this data is largely incomplete (Hallin et al., 2020b). Taken together, 
it is clear that KRAS G12C inhibitors have promise as a means of abrogating Ras-mediated resistance, 
although there remain drawbacks which need assessing. Most notably, the lack of efficacy against 
other Ras mutations, which are prevalent across Ras-mutated disease. 
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Clearer understanding of the structure of Ras has not only permitted elucidation of the SII-P pocket, 
but also alternative binding sites, including a pocket between the Switch I and II regions of Ras (termed 
pocket I). Key residues available for interaction with small molecule compounds include K5, L6, V7, V8, 
S39, D54, I55, L56, Y71, T74, G75 and E76 (Maurer et al., 2012; Quevedo et al., 2018). Antibody-
fragment-directed site exploration can be used to explore and exploit previously unconsidered drug 
interaction sites. In the case of Ras, this mechanism has been used to analyse potential compound 
binding sites within the previously-identified pocket I, that could be targeted using small molecule 
inhibitors to interrupt effector proteins (such as c-RAF and p110) from binding to Ras via the Ras 
binding domain (RBD) (Maurer et al., 2012; Quevedo et al., 2018). This would provide an alternative 
mechanism of abrogating the effects of oncogenic Ras activation to those discussed previously, and 
early results showed effectiveness of antibody-derived compounds against a range of Ras mutations 
and isoforms (Quevedo et al., 2018). However, given high affinity binding of certain effectors to Ras 
(such as PI3K and B-RAF, with 3.2 µM and 0.04 µM affinity respectively) (Erijman & Shifman, 2016), 
the high EC50s of the compounds identified in these in vitro assays mean that many further 
modifications would be required to convert these putative compounds into usable therapeutics. 
Nevertheless, such antibody-derived fragments have the potential to be fused with small molecule 
protein-protein interaction (PPI) inhibitors to improve efficacy (Cruz-Migoni et al., 2019). Whilst many 
Ras-effector interaction inhibitors have been trialled pre-clinically, none have been implemented in 
the clinic in the context of Ras-mutant cancer, owing to lack of efficacy, or toxicity potential (Canon et 
al., 2019; Keeton, Salter & Piazza, 2017). However, crystal structure determination showed that fusion 
of compounds developed through antibody-derived fragment screening with known small molecule 
PPI inhibitors results in better binding within pocket I, thus inhibiting Ras-effector interactions with a 
lower EC50. Nevertheless, the therapeutic use of pocket I may be restricted since such a pocket has 
also been detected in wild-type Ras (Cruz-Migoni et al., 2019), thus increasing the risk for on-target 
toxicity.  
In recent times, inhibition of the Ras-effector interaction has been seen through competitive binding 
of rigosertib at the RBD. This compound elicits effects against MAPK, PI3K and RAL pathway activation, 
in both wild-type and mutant Ras situations (Athuluri-Divakar et al., 2016). Inhibition of multiple Ras-
mediated diseases have been seen in response to rigosertib, including pancreatic cancer and 
leukaemia (Athuluri-Divakar et al., 2016; Baker, Cosenza, Ramana Reddy & Premkumar Reddy, 2019). 
Rigosertib is moderately to well- tolerated in clinical trials thus far, although is yet to be specifically 
tested in the context of Ras-mutant cancer (Bowles et al., 2014; Ma et al., 2012; Navada et al., 2020). 
As with the antibody-derived, small molecule PPI inhibitors described above, toxicity may be as a result 
of rigosertib’s ability to target both wild-type and mutant KRAS, and thus further studies are needed 
to fully assess the impact such a drug on healthy cells.  
Antibody therapy is also currently being explored as means of direct Ras-targeting. However, a major 
drawback has been the capability of the antibody to cross the cell membrane, as with any protein 
based therapy (Bolhassani, Jafarzade & Mardani, 2017). Therefore, the development of inRas37, a 
pan-Ras targeting antibody, is a considerable step forward in targeting Ras. Although the cellular 
uptake remains low (approximately 4%), in vitro and in vivo work has shown promise in the potential 
of inRas37 to inhibit both the MAPK and PI3K-AKT pathways, in a dose-dependent manner (Shin et al., 
2020). Briefly, this drug binds to integrins V3 and V5 on the cancer cell surface which then 
undergo endocytosis. The antibody ‘escapes’ the endosome as a result of pH-determined cleavage 
(the antibody is cleaved from the integrins better at pH 7, the cytoplasmic pH, compared to pH 6.5, 
the pH of early endosomes) (Podinovskaia & Spang, 2018; Putnam, 2012; Shin et al., 2020). The 
antibody then co-localises with Ras to block the effector binding site, in a manner similar to the PPI 
inhibitors described above. Mutations introduced into the general antibody structure render it specific 
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for mutant Ras binding, with little activity against Ras wild-type, thereby limiting on-target toxicity. 
inRas37 has greater effect on cells with a greater dependency on Ras signalling, which can include 
some tumour cells (Weinstein, 2002; Yi, Nissley, McCormick & Stephens, 2020). Nevertheless, when 
tested on large tumour models (spheroids and cell-derived xenograft mice), efficacy decreased 
considerably (Shin et al., 2020). This therefore shows that treatment with this drug may be suitable 
for patients at earlier stages of Ras-mutated cancer, before tumour burden is too great and reduces 
drug efficacy. Thus, it could be used to treat Ras-initiated relapse as soon as it occurs, however its 
utility in eliminating minor subclones prior to relapse is limited, given the low cellular uptake and the 
need for a high Ras dependency in the cell. 
Resistance to Ras Targeting Agents 
Of course, there is potential for resistance to any therapeutic, and Ras-targeting drugs are no different. 
Some of these have been previously discussed here, such as the use of geranylgeranyltransferase to 
overcome the effects of farnesyltransferase inhibitors (Whyte et al., 1997), or the upregulation of 
alternative Ras-mediated pathways, as seen when patients are treated with MEK inhibitors (Vitiello et 
al., 2019). Other mechanisms of resistance are also possible, such as the re-activation of ERK, which 
may be a potential resistance mechanism in the case of a Ras-targeting agent (Bruner et al., 2017; 
Ercan et al., 2012; Ochi et al., 2014). This has already been seen in the case of EGFR-inhibitor 
resistance, whereby negative regulators of ERK are downregulated, so pro-apoptotic BIM is not fully 
upregulated and so cannot fully induce apoptosis. Alternatively, the gene encoding ERK1, MAPK1, is 
amplified. These scenarios resulted in in vitro and in vivo resistance to the putative EGFR inhibitor 
WZ4002 (Ercan et al., 2012). ERK-reactivation has also been found to contribute to gefitinib resistance, 
but in this case, was found to be mediated by Src (Ochi et al., 2014). Given these kinases are either 
side of Ras, their co-operation could result in resistance to a Ras inhibitor. However, Src-mediated ERK 
reactivation is avoidable through treatment with Src inhibitors (Ochi et al., 2014), which may present 
a means of overcoming this potential Ras-inhibitor resistance mechanism. Taken together, these 
studies imply that, while resistance to Ras-targeting drugs is possible, there are already means of 
overcoming this resistance, just as a Ras-targeting drug would provide the means of overcoming Ras-
mediated resistance.  
Whilst other elements of pathways contributing to resistance can be targeted relatively easily, 
acquisition of secondary mutations in Ras present a more pressing problem. For example, at present, 
the G12C specific inhibitor is perhaps the most developed means of inhibiting Ras, however a 
subsequent mutation in Ras would most likely render this inhibitor ineffective. This has already been 
evidenced in studies into KRAS G12C inhibitors, whereby rescue experiments with the G12V mutation 
restored the cancerous phenotype (Ostrem, Peters, Sos, Wells & Shokat, 2013). Therefore, a pan-
mutation targeting drug, such as a derivative of inRas37, may be favoured.  
Discussion 
Ras mutations in cancer and chemoresistance are important when considering patient prognosis. 
Whilst it seems inevitable that resistance will be an issue for a long time to come, better targeting of 
potential causes is imperative. Advances in Ras inhibition could help reduce the risk of resistance and 
relapse for a wide range of cancers, given its mutational frequency. At present, some success has been 
seen when multiple drugs are used to target different pathways implicated in Ras-mutated disease. 
However, other studies have shown lack of long-term efficacy when combining multiple therapies. 
Therefore, single agent, multi-pathway targeting agents, including direct Ras inhibitors are becoming 
more heavily researched. It will be interesting to see the effects of these in vivo, since this type of 
therapy may reduce the potential for future development of drug resistance by upregulation of an 
alternative pathway. Targeting a common factor at the centre of multiple pathways may target more 
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cancer cell types and thus reduce the heterogeneity of the tumour, eliminating potential resistance 
causes before they become dominant.  
Previous failures of Ras-targeting agents, including farnesyltransferase inhibitors, as well as perceived 
unfavourable protein dynamics, has resulted in Ras being largely considered undruggable. However, 
development of structural analysis techniques and a clearer understanding of the key residues in Ras 
has altered this thinking, with new compounds with novel, allele-specific Ras binding mechanisms 
showing great promise. Phase I trials of AMG-510, a first-in-class direct Ras-targeting agent, suggest a 
turning point has been reached in this field of study. Whilst there is much more to be done, these 
preliminary data indicate a solution for Ras-mediated resistance may be possible.  
Nevertheless, a greater understanding of resistance must be gained before relapse risk can be 
eliminated. Despite evidence supporting the CSC theory, limited standard-of-care detection 
sensitivities for initial diagnostic samples prevent identification of the minor subclones present at 
diagnosis (McMahon et al., 2019). It can therefore be difficult to determine likely causes of relapse 
upon initial diagnosis, and so constant monitoring for changes in expression of genes commonly 
implicated in drug resistance, such as Ras, may provide a useful tool for predicting disease trajectory. 
Nevertheless, this is only useful if the effects of the acquired/emergent mutations can be abrogated. 
In the cases discussed here, improved analytical tools would ideally be combined with Ras-targeting 
agents to prevent resistance taking hold.  
Ultimately, chemoresistance, either intrinsic or acquired, due to Ras mutations, whether primary or 
secondary, remains a considerable problem. The concepts presented here, amongst many other 
examples, illustrate the necessity for Ras-targeting drugs. There is a distinct clinical requirement for 
the improved targeting of Ras in cancer, with Ras implicated in both initial disease presentation and 
relapse. Although no universal, direct Ras inhibitor has yet been achieved, considerable progress has 
been made in the last decade with the advent of allele-specific inhibitors. This brings promise to the 
field, with the potential for better treatment of Ras-initiated resistance a real prospect. 
 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2019/20 (Alexander et al., 2019). 
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Figure Legends. 
Figure 1: The impact of Ras alterations on disease. Data collected from 32 curated, non-redundant 
studies, comprising 10967 patient samples, as collated by the TCGA pan-Cancer Atlas.  A) 10 year 
profession-free survival (PFS) analysis for patients with and without Ras alterations . Ras wild-type 
(blue) vs. altered (red) overall survival. Ras wild-type median PFS = 65.88 months, Ras-altered median 
PFS = 44.19 months. P<0.01. B) 10 year PFS stratified by altered Ras isoform. KRAS (orange) median 
PFS = 36.72 months, NRAS (green) median PFS = 45.67 months, HRAS (purple) median PFS = 74.89 
months. P<0.01. C) Cancer types where KRAS is altered in at least 10% of cases. D) Cancer types where 
NRAS is altered in at least 10% of cases. E) Cancer types where HRAS is altered in at least 10% of cases. 
Data obtained from cBioPortal, all TCGA PanCancer Atlas Studies. 
 
Figure 2: 2D and 3D representation of the structure of RAS. A) physiological binding domains. B) key 
structural domains (switch regions and lobes), with mutational hotspots G12, G13 and Q61 indicated. 
Redrawn from Prior et al., 2012. 3D structures based on PDB 4DST.  
 
Figure 3: RAS-mediated pathways and associated inhibitors. Targets of small molecule inhibitors and 
monoclonal antibodies used across a range of cancers to inhibit proliferative signalling and survival of 
cancer cells. Figure includes examples of compounds identified in vitro, those which have progressed 
into trials and those which are approved.  
  pre-clinical studies,  phase I clinical trials,   phase II clinical trials,  FDA approved use. Further 
detail is provided in table 1.  
 
Figure 4: Evolution of novel direct RAS-targeting agents. Chemical structure and protein structures 
of RAS direct targeting agents in complex with GDP-bound (pink) KRAS. A) Minor modification of initial 
compound hit 6H05,  6H05 compound 6 (purple) bound covalently to KRAS G12C, PDB accession no.  
4LUC. B) ARS-853 (purple) bound covalently to KRAS G12C (orange), PDB accession no. 5F2E. C) ARS-
1620 (purple) bound covalently to KRAS G12C (orange), PDB accession no. 5V9U. D) AMG-510 (purple) 
bound to KRAS G12C (orange), PDB accession no. 6OIM. E) MRTX849 (purple)  bound covalently to 
KRAS G12C (orange), PDB accession no. 6UT0. Molecules shown in relation to the switch regions, 
largely binding in SII-P. All compounds bind covalently near to mutational hotspot. 
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Table 1: Summary of current Ras pathway targeting drugs, at varying stages of development. 
Name  Drug Type Target Development 
Stage 
Mode of inhibition Selected common 
adverse effects  
References 
Gilteritinib Pyrazinecarboxamide, 
small molecule inhibitor 
FLT3-ITD, FLT3-
TKD, AXL 
FDA-Approved Binds active FLT3 (either ITD 
or TKD), inhibiting 
constitutive signalling 
Acute kidney injury, 
hypotension, diarrhoea, 
dizziness 
Lee et al. (2017); 
Perl et al. (2019) 
Midostaurin Indolocarbazole, small 
molecule inhibitor 
FLT3 FDA-Approved Binds active FLT3, inhibiting 
constitutive signalling  
Nausea, neutropenia, 
thrombocytopenia, 
diarrhoea, vomiting 
Levis (2017); Stone 
et al. (2012) 
Crenolanib Benzamidazole-
derivative small 
molecule inhibitor 
FLT3-ITD, FLT3-TKD Phase II 
(NCT02400255) 
Binds active FLT3, inhibiting 
constitutive signalling  
Nausea, vomiting, 
diarrhoea, stomach 
pain 
Galanis et al. 
(2014); Marensi, 
Keeshan and 
MacEwan (2021); 
Wu, Li and Zhu 
(2018) 
Cetuximab Chimeric IgG1 chimeric 
monoclonal antibody 
EGFR FDA-Approved Competitively binds 
extracellular domain of EGFR, 
preventing ligand-mediated 
signalling  
Oedema, fatigue, 
anorexia, rash, 
vomiting 
Jonker et al. (2007) 
Panitumumab Human IgG2 
Monoclonal antibody 
EGFR FDA-Approved Competitively binds 
extracellular domain of EGFR, 
inhibiting EGFR dimerization 
and autophosphorylation  
Rash, diarrhoea, 
hypomagnesaemia 
Van Cutsem et al. 
(2007) 
BAY293 Quinazoline-based small 
molecule inhibitor 
SOS1 Pre-clinical Disruption of the KRAS-SOS1 
interaction, reducing 
exchange of GDP for GTP 
N/A Hillig et al. (2019) 
SAH-SOS1 Stapled peptide 
fragment 
SOS1 Pre-clinical Binds KRAS (active or 
inactive) in the SOS1 binding 
pocket, reducing GTP binding 
to KRAS  
N/A Leshchiner et al. 
(2015) 
c Small molecule inhibitor SOS1 Phase I 
(NCT04111458) 
Binds inside the catalytic site 
of SOS1, preventing 
interaction with (and 
activation of) KRAS 
N/A Gerlach et al. 
(2020) 
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KYA1797K Thiazolidine-based 
small molecule inhibitor 
Axin Pre-clinical  Binds to the RGS domain of 
Axin, causing formation of 
the -catenin destruction 
complex, subsequently 
destabilising Ras 
N/A Cha et al. (2016); 
Lee et al. (2018) 
Tipifarnib Quinolinone small 
molecule inhibitor 
Farnesyltransferase FDA-Approved Prevents Ras farnesylation 
and subsequent trafficking to 
the membrane 
Thrombocytopenia, 
Anorexia, anaemia, 
nausea, neutropenia 
Duffy and Crown 
(2021); Lee et al. 
(2020) 
ARS-853 Acrylamide-based, small 
molecule inhibitor  
KRAS-G12C Pre-clinical Irreversible binding to KRAS-
G12C SII-P pocket, inhibiting 
exchange of GDP for GTP 
N/A Lito, Solomon, Li, 
Hansen and Rosen 
(2016); Patricelli et 
al. (2016)  
ARS-1620 Acrylamide-based, small 
molecule inhibitor (S-
atropisomer) 
KRAS-G12C Pre-clinical Irreversible binding to KRAS-
G12C SII-P pocket, inhibiting 
exchange of GDP for GTP 
N/A Janes et al. (2018)  
AMG-510 Acrylamide-based, small 
molecule inhibitor 
KRAS-G12C Phase I/II 
(NCT03600883) 
Irreversible binding to KRAS-
G12C SII-P pocket, inhibiting 
exchange of GDP for GTP 
Anaemia, diarrhoea Canon et al. (2019); 
Govindan (2019) 
MRTX849 Acrylamide-based, small 
molecule inhibitor 
KRAS-G12C Phase I 
(NCT03785249) 
Covalent binding in SII-P 
pocket, inhibiting exchange 
of GDP for GTP  
Nausea, diarrhoea, 
fatigue, hyponatremia 
Fell et al. (2020); 
Hallin et al. (2020a) 
inRas37 Human IgG1 
internalising and PPI-
interfering monoclonal 
antibody  
pan-Ras Pre-clinical Competitive inhibition of 
RAS-effector interaction  
N/A Shin et al. (2020) 
siG12D-
LODER 
Long-acting siRNA  KRAS-G12D Phase II 
(NCT01676259) 
siRNA-mediated KRAS G12D 
silencing  
Diarrhoea, abdominal 
pain, nausea, fatigue 
Golan et al. (2015); 
Zorde Khvalevsky 
et al. (2013) 
Dabrafenib Sulphonamide-based 
small molecule inhibitor 
BRAF (wild-type 
and V600-mutated) 
FDA-Approved ATP-competitive inhibitor; 
binds active BRAF and thus 
inhibits downstream effector 
activation  
Rash, fever, fatigue, 
headache, 
hypertension, 
arthralgia 
Bowyer, Lee, Fusi 
and Lorigan (2015); 
King et al. (2013); 
Rheault et al. 
(2013) 
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Vemurafenib Azaindole-derived small 
molecule inhibitor 
BRAF-V600E FDA-Approved ATP-competitive inhibitor, 
binds active BRAF and thus 
inhibits downstream receptor 
activation  
Skin lesions (including 
squamous cell 
carcinoma), arthralgia, 
fatigue 
Sharma, Shah, 
Illum and Dowell 
(2012); Tsai et al. 
(2008) 
Sorafenib Biaryl-urea-based small 
molecule inhibitor 
RAF, PDGFR, 
VEGFR amongst 
others  
FDA-Approved Binds inactive conformation 
of BRAF, reducing activation. 
Also sequesters Raf into 
inactive complexes. 
Diarrhoea, weight loss, 
skin reactions, alopecia, 
voice changes 
Adnane, Trail, 
Taylor and Wilhelm 
(2006); Llovet et al. 
(2008); (Marensi, 
Keeshan & 
MacEwan, 2021); 
Wan et al. (2004); 
Wilhelm et al. 
(2006) 
Cobimetinib Carboxamide-based 
small molecule inhibitor 
RAF, MEK FDA-Approved Non-ATP-competitive 
inhibitor, binds active MEK, 
inhibiting downstream ERK 
activation 
Diarrhoea, rash, 
fatigue, arthralgia, 
photosensitivity 
Garnock-Jones 
(2015); 
Hatzivassiliou et al. 
(2013); Rice et al. 
(2012)  
Trametinib Pyridopyrimidine small 
molecule inhibitor 
MEK FDA-Approved ATP non-competitive kinase 
inhibitor; binds the kinase 
suppressor of RAS-RAS 
interface, reducing MEK 
phosphorylation 
Diarrhoea, rash, blurred 
vision 
Borthakur et al. 
(2016); Khan et al. 
(2020)  
LY3214996 Thiazolone-based small 
molecule inhibitor 
ERK Phase I 
(NCT02857270) 
ATP-competitive inhibitor, 
reversibly binds ERK1 and 
ERK2, causes cell cycle arrest 
in G1 and initiates apoptosis 
Nausea, vomiting, 
diarrhoea, fatigue, 
blurred vision 
Bhagwat et al. 
(2020); Pant et al. 
(2019) 
RBC8 Carbonitrile-based small 
molecule inhibitor 
RAL Pre-clinical  Non-ATP-competitive 
inhibitor, binds GDP-loaded 
RAL, preventing activation 
N/A Walsh, Wersäll and 
Poole (2019); Yan 
et al. (2014) 
Alpelisib Aminothiazole-based 
small molecule inhibitor 
PI3K FDA-Approved ATP-competitive inhibitor, 
binds selectively to PI3K 
Hyperglycaemia, rash, 
diarrhoea, nausea, 
decreased appetite 
André et al. (2019); 
Furet et al. (2013)  
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Uprosertib Thiophenecarboxemide-
based small molecule 
inhibitor 
AKT Phase II 
(NCT01902173) 
ATP-competitive inhibitor, 
binds AKT and reduces 
downstream signalling  
Nausea, vomiting, 
diarrhoea, rash 
Gungor et al. 
(2015); Nitulescu et 
al. (2016) 
Everolimus Macrocyclic lactone-
based small molecule 
inhibitor 
mTOR FDA-Approved Complexes with FKBP12, 
which binds mTOR and 
inhibits activation 
Leukopenia, 
hypercholesterolaemia, 
hyperlipidaemia  
Dunn and Croom 
(2006) 
 
 
 
